Enpatoran

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Renal ImpairmentSystemic Lupus Erythematosus (SLE)

15 competitors in Renal Impairment

#DrugCompanyPhaseTrials

1

Zyvox

Pfizer

Approved

12

Fludara

Sanofi

Phase 1

13

Enpatoran

Merck & Co.

Phase 3

14

Grafapex

MMedexus Pharma, Inc.

Phase 1

15

Nemtabrutinib

Merck & Co.

Phase 1

16

Wayrilz

GGenzyme, a Sanofi Company

Phase 1

17

D-2570

IInventisBio Co., Ltd

Phase 1

18

ASTX727

Taiho Oncology, Inc.

Phase 1

19

GZR18

GGan & Lee Pharmaceuticals.

Phase 1

110

PKN605

Novartis

Phase 1

1Show 6 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus (SLE)2 trials

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-1)

Recruiting·EMD Serono Research & Development Institute, Inc.·Phase 3·NCT07332481·202 enrolled

A Phase 3, Single-Arm, Open-Label, Long-Term Extension Study To Evaluate The Safety And Efficacy Of Enpatoran In Participants With Active Cutaneous Manifestations Of Lupus Erythematosus With Or Without Systemic Disease Receiving Standard Of Care [Elowen-LTE]

Not yet recruiting·EMD Serono Research & Development Institute, Inc.·Phase 3·NCT07840287·404 enrolled

Renal Impairment1 trial

Effect of Renal Impairment on Enpatoran Pharmacokinetics

Recruiting·Merck & Co.·Phase 1·NCT06589713·40 enrolled

SLE1 trial

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Completed·EMD Serono Research & Development Institute, Inc.·Phase 2·NCT05162586·456 enrolled

Cardiac Repolarization1 trial

A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants

Completed·Merck & Co.·Phase 1·NCT06589726·40 enrolled

Lupus Erythematosus1 trial

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-2)

Recruiting·EMD Serono Research & Development Institute, Inc.·Phase 3·NCT07355218·202 enrolled

1 more indication

Unspecified1 trial

Enpatoran Human Mass Balance and Absolute Bioavailability Study

Completed·Merck & Co.·Phase 1·NCT05110027·7 enrolled

Details

Drug Info

Related News